Compare CENX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CENX | HTFL |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 1996 | 2025 |
| Metric | CENX | HTFL |
|---|---|---|
| Price | $36.03 | $30.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $33.00 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 1.9M | 733.8K |
| Earning Date | 11-06-2025 | 02-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,525,100,000.00 | $161,881,000.00 |
| Revenue This Year | $16.07 | $40.42 |
| Revenue Next Year | N/A | $22.27 |
| P/E Ratio | $43.42 | ★ N/A |
| Revenue Growth | 20.15 | ★ 85.70 |
| 52 Week Low | $13.05 | $25.38 |
| 52 Week High | $37.05 | $41.22 |
| Indicator | CENX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 71.87 | N/A |
| Support Level | $31.71 | N/A |
| Resistance Level | $33.06 | N/A |
| Average True Range (ATR) | 1.52 | 0.00 |
| MACD | 0.50 | 0.00 |
| Stochastic Oscillator | 86.85 | 0.00 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.